Outcomes In Patients With Asthma and Coexisting Allergic Rhinitis Who Started Dupilumab Treatment In Real-World Clinical Practice: A RAPID Registry Study
Author(s)
Andréanne Côté, MD1, Xavier Muñoz, PhD2, David Price, PhD3, Giselle S. Mosnaim, MD4, Changming Xia, PhD5, Hashem Awad, MD6, Jason H. Kwah, PhD5.
1Quebec Heart and Lung Institute – Laval University, Quebec, QC, Canada, 2Hospital Vall d’Hebron, Barcelona, Spain, 3Observational and Pragmatic Research Institute, Midview City, Singapore, 4Endeavor Health, Evanston, IL, USA, 5Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA, 6Sanofi, Cambridge, MA, USA.
1Quebec Heart and Lung Institute – Laval University, Quebec, QC, Canada, 2Hospital Vall d’Hebron, Barcelona, Spain, 3Observational and Pragmatic Research Institute, Midview City, Singapore, 4Endeavor Health, Evanston, IL, USA, 5Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA, 6Sanofi, Cambridge, MA, USA.
Presentation Documents
OBJECTIVES: Allergic rhinitis (AR) commonly coexists with asthma. Patients starting dupilumab for asthma in real-world practice were enrolled in the global RAPID registry (NCT04287621). We used 12 months of RAPID data to assess changes in asthma severity and patient-reported outcomes in patients with or without coexisting AR.
METHODS: Patients aged ≥12 years starting dupilumab for asthma were assessed at baseline, 1 month, and every 3 months. This analysis evaluated annualized rates of severe exacerbation and changes from baseline in scores on the 6-item Asthma Control Questionnaire (ACQ-6), Mini Asthma Quality of Life Questionnaire (MiniAQLQ), Allergic Rhinitis Visual Analog Scale (AR-VAS), and Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ). All data reported are mean (SD) unless otherwise stated.
RESULTS: Of 205 patients assessed, 167 (81.5%) had AR. The time since asthma diagnosis was longer in patients with AR than without (21.9 [18.6] vs 16.2 [13.6] years). Prior to enrollment, asthma exacerbations were higher in patients with AR (n = 76; 2.1 [4.5]) than without AR (n = 11; 1.1 [2.8]). After 12 months of dupilumab, unadjusted annualized severe exacerbation rates dropped to 0.136 in patients with AR, and 0.140 in those without. ACQ-6 scores at baseline, 6 and 12 months were 2.36 (1.21), 1.03 (0.99) and 0.99 (1.08) for patients with AR vs 2.26 (1.11), 1.51 (1.03) and 1.03 (0.96) for those without. Similarly, MiniAQLQ scores were 4.02 (1.28), 5.48 (1.29) and 5.54 (1.37) for patients with AR, and 4.40 (1.47), 5.56 (1.22) and 5.42 (1.38) for those without. Among patients with AR, at 12 months, AR-VAS and RQLQ scores decreased by 23.5 (32.8) points and 0.84 (1.34) points, respectively.
CONCLUSIONS: Asthma patients with or without AR treated with dupilumab had fewer exacerbations, better asthma control, and improved asthma-related quality of life. Those with AR also reported reduced symptoms and enhanced AR-related quality of life.
METHODS: Patients aged ≥12 years starting dupilumab for asthma were assessed at baseline, 1 month, and every 3 months. This analysis evaluated annualized rates of severe exacerbation and changes from baseline in scores on the 6-item Asthma Control Questionnaire (ACQ-6), Mini Asthma Quality of Life Questionnaire (MiniAQLQ), Allergic Rhinitis Visual Analog Scale (AR-VAS), and Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ). All data reported are mean (SD) unless otherwise stated.
RESULTS: Of 205 patients assessed, 167 (81.5%) had AR. The time since asthma diagnosis was longer in patients with AR than without (21.9 [18.6] vs 16.2 [13.6] years). Prior to enrollment, asthma exacerbations were higher in patients with AR (n = 76; 2.1 [4.5]) than without AR (n = 11; 1.1 [2.8]). After 12 months of dupilumab, unadjusted annualized severe exacerbation rates dropped to 0.136 in patients with AR, and 0.140 in those without. ACQ-6 scores at baseline, 6 and 12 months were 2.36 (1.21), 1.03 (0.99) and 0.99 (1.08) for patients with AR vs 2.26 (1.11), 1.51 (1.03) and 1.03 (0.96) for those without. Similarly, MiniAQLQ scores were 4.02 (1.28), 5.48 (1.29) and 5.54 (1.37) for patients with AR, and 4.40 (1.47), 5.56 (1.22) and 5.42 (1.38) for those without. Among patients with AR, at 12 months, AR-VAS and RQLQ scores decreased by 23.5 (32.8) points and 0.84 (1.34) points, respectively.
CONCLUSIONS: Asthma patients with or without AR treated with dupilumab had fewer exacerbations, better asthma control, and improved asthma-related quality of life. Those with AR also reported reduced symptoms and enhanced AR-related quality of life.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
CO143
Topic
Clinical Outcomes
Topic Subcategory
Clinical Outcomes Assessment
Disease
SDC: Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory), STA: Biologics & Biosimilars